Results 241 to 250 of about 75,041 (254)

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Lancet, The, 2002
Mette Zander, Sten Madsbad, Jens J Holst   +2 more
exaly  

Transcription Factor FoxO1 Mediates Glucagon-Like Peptide-1 Effects on Pancreatic  -Cell Mass

Diabetes, 2006
Jean Buteau, Domenico Accili, Buteau Jean   +2 more
exaly  

A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity

Circulation, 2013
Ilya Mukovozov, Ren-Ke Li, Allen Volchuk   +2 more
exaly  

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

Hypertension, 2012
Limei Liu, Wing Tak Wong, Xiao Yu Tian
exaly  

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

Gastroenterology, 2011
Aleksey V Matveyenko, Robert Elashoff, Peter C Butler   +2 more
exaly  

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Diabetes Care, 2007
Tina VILSBØLL, Milan Zdravković, Thure Krarup   +2 more
exaly  

Glucagon-Like Peptide-1

2010
openaire   +1 more source

Glucagon-like-peptide-1

Reactions Weekly, 2014
openaire   +1 more source

The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective

Human Reproduction Update, 2019
Mojca Jensterle, Andrej Janez, Eric Fliers   +2 more
exaly  

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus

Circulation, 2019
Thomas A Zelniker, Itamar Raz, Kyungah Im   +2 more
exaly